Losartan and fetal toxic effects

We report a case of maternal exposure to the antihypertensive drug losartan during weeks 20–31 of pregnancy. We saw the fetal toxic effects of oligohydramnios (decreased amniotic fluid), fetal pulmonary hypoplasia, fetal hypoplastic skull bones, and subsequent fetal death. This pattern of abnormalities is similar to those seen in exposure to angiotensin-converting- enzyme (ACE) inhibitors during pregnancy, and were probably caused by losartan.